Yahoo
    Shanghai - Delayed Quote CNY

    RemeGen Co., Ltd. (688331.SS)

    92.06 -1.56 (-1.67%)
    At close: October 30 at 3:00:00 PM GMT+8
    Loading Chart for 688331.SS
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    RemeGen (SEHK:9995) Stock Faces Q3 Earnings Doubts Despite Profit Swing

    RemeGen (SEHK:9995) Stock Faces Q3 Earnings Doubts Despite Profit Swing
    Simply Wall St. 1d ago
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
    GlobeNewswire 9d ago
    RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run

    RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run
    Simply Wall St. 12d ago
    Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

    Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
    GlobeNewswire 1mo ago
    Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

    Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
    GlobeNewswire 4mo ago
    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
    GlobeNewswire 5mo ago
    Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

    Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
    GlobeNewswire 5mo ago
    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development
    PR Newswire 3d ago
    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development
    PR Newswire 3d ago
    Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

    Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
    GlobeNewswire 6mo ago
    Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

    Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
    GlobeNewswire 4mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: